Cargando…

Ipilimumab augments antitumor activity of bispecific antibody-armed T cells

BACKGROUND: Ipilimumab is an antagonistic monoclonal antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4) that enhances antitumor immunity by inhibiting immunosuppressive activity of regulatory T cells (Treg). In this study, we investigated whether inhibiting Treg activity with ipilimumab duri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yano, Hiroshi, Thakur, Archana, Tomaszewski, Elyse N, Choi, Minsig, Deol, Abhinav, Lum, Lawrence G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105782/ https://www.ncbi.nlm.nih.gov/pubmed/25008236 http://dx.doi.org/10.1186/1479-5876-12-191

Ejemplares similares

Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS)
por: Lum, Lawrence G, et al.
Publicado: (2015)

Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients
por: Lum, Lawrence G., et al.
Publicado: (2020)

Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness
por: Thakur, Archana, et al.
Publicado: (2021)

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies
por: Zitron, Ian M, et al.
Publicado: (2013)

Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells
por: Thakur, Archana, et al.
Publicado: (2021)

Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer
por: Lum, Lawrence G., et al.
Publicado: (2021)

Vaccination with bispecific antibody armed T cells (BATC) in metastatic breast cancer patients and transfer of anti-breast cancer immunity in primed T cells after stem cell transplant: a proof of principle study
por: Thakur, Archana, et al.
Publicado: (2015)

In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer
por: Thakur, Archana, et al.
Publicado: (2015)

Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia
por: Kubicka, Ewa, et al.
Publicado: (2022)

LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer
por: Qiao, Guilin, et al.
Publicado: (2022)

Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE(2) dependent pathway
por: Thakur, Archana, et al.
Publicado: (2013)

Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1(+) Myeloma Cells and Release Type-1 Cytokines
por: Lum, Lawrence G., et al.
Publicado: (2020)

Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells
por: Urbanska, Katarzyna, et al.
Publicado: (2014)

MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody
por: Li, Hongjian, et al.
Publicado: (2020)

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients
por: Vaishampayan, Ulka, et al.
Publicado: (2015)

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
por: Park, Jeong A, et al.
Publicado: (2023)

Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release
por: Park, Jeong A, et al.
Publicado: (2021)

Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells
por: Yankelevich, Maxim, et al.
Publicado: (2023)

Enhancing the antitumor potency of T cells redirected by bispecific antibodies
por: Chang, Chien-Hsing, et al.
Publicado: (2017)

Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
por: Wang, Zhaoming, et al.
Publicado: (2021)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
por: Lutz, Martina Svenja, et al.
Publicado: (2022)

Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours
por: Huang, Manley T. F., et al.
Publicado: (2022)

T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
por: Kamakura, Daisuke, et al.
Publicado: (2021)

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
por: Kauer, Joseph, et al.
Publicado: (2020)

Bispecific Antibodies for Diagnostic Applications
por: Parashar, Archana, et al.
Publicado: (2011)

Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity
por: Faber, Mary L., et al.
Publicado: (2023)

A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
por: Satta, Alessandro, et al.
Publicado: (2019)

Bispecific antibodies with Fab-arms featuring exchanged antigen-binding constant domains
por: Benedetti, Filippo, et al.
Publicado: (2021)

Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities
por: Yanakieva, Desislava, et al.
Publicado: (2022)

PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy
por: Shi, Ning, et al.
Publicado: (2022)

Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity
por: Dheilly, Elie, et al.
Publicado: (2018)

Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies
por: Park, Jeong A, et al.
Publicado: (2022)

Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer
por: Liu, Shiyu, et al.
Publicado: (2023)

B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8(+) tumor-infiltrating lymphocytes
por: You, Gihoon, et al.
Publicado: (2021)

An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers
por: Wang, Ninghai, et al.
Publicado: (2021)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)

LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation
por: Sung, Eunsil, et al.
Publicado: (2022)

Kinetic mechanism of controlled Fab-arm exchange for the formation of bispecific immunoglobulin G1 antibodies
por: Goulet, Dennis R., et al.
Publicado: (2018)

Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer
por: Kim, Da-Hyun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2mjrni41c275snj2di2tt3eab9